Jupiter Topco LLC Invests $1.97 Billion in Johnson & Johnson $JNJ

Jupiter Topco LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 7,746,487 shares of the company’s stock, valued at approximately $1,967,399,000. Johnson & Johnson accounts for approximately 0.8% of Jupiter Topco LLC’s investment portfolio, making the stock its 24th largest holding.

A number of other institutional investors also recently added to or reduced their stakes in JNJ. American Trust increased its position in Johnson & Johnson by 0.9% during the 2nd quarter. American Trust now owns 29,039 shares of the company’s stock worth $7,375,000 after purchasing an additional 255 shares during the period. Delos Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 3.0% in the 2nd quarter. Delos Wealth Advisors LLC now owns 2,383 shares of the company’s stock valued at $605,000 after buying an additional 70 shares during the period. Canada Pension Plan Investment Board lifted its holdings in shares of Johnson & Johnson by 16.3% in the 2nd quarter. Canada Pension Plan Investment Board now owns 5,284,214 shares of the company’s stock valued at $1,342,032,000 after buying an additional 739,792 shares during the period. Kinloch Capital LLC boosted its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Kinloch Capital LLC now owns 20,931 shares of the company’s stock valued at $5,316,000 after buying an additional 193 shares in the last quarter. Finally, White Knight Strategic Wealth Advisors LLC grew its holdings in Johnson & Johnson by 1.2% during the second quarter. White Knight Strategic Wealth Advisors LLC now owns 26,121 shares of the company’s stock worth $6,634,000 after acquiring an additional 309 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Guggenheim boosted their price objective on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Bank of America upped their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $272.83.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst sentiment remains supportive. JNJ received an upgrade that helped it reach a new 12-month high, while the broader analyst view is rated “Moderate Buy.” UBS also began coverage, potentially increasing institutional attention. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade Johnson & Johnson Receives Average Rating of Moderate Buy
• Positive Sentiment: Johnson & Johnson’s 64-year record of dividend growth remains a key support for income-oriented investors. Strong profitability and the company’s diversified healthcare portfolio help sustain the dividend despite competitive pressure on a major drug. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Neutral Sentiment: Management will discuss the business at the Deutsche Bank Healthcare Summit on September 17. The event could provide updates on pharmaceuticals, litigation and forward guidance, but it is not itself a change to earnings expectations. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: Profit-taking and valuation risk are elevated after JNJ gained about 60% over the past year versus roughly 21% for the S&P 500. Analysts question whether the current price already discounts growth above management’s near-term outlook. Was JNJ Stock Rally Actually Its Own? Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
• Negative Sentiment: An executive vice president sold 33,597 shares worth approximately $9.2 million, reducing his holdings by 56.9%. The sale may reinforce short-term concerns about insider conviction, although it does not change JNJ’s fundamentals. SEC insider transaction filing
• Negative Sentiment: An analyst lowered the FY2026 EPS forecast, adding pressure to expectations. Talc litigation also remains unresolved despite a proposed path toward settlement, while the Louisiana verdict continues to focus attention on legal liability and potential costs. Johnson & Johnson dividend and competition analysis

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kathryn Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 97,569 shares of company stock valued at $25,476,044. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.0%

Johnson & Johnson stock opened at $275.12 on Monday. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The firm has a market capitalization of $663.01 billion, a price-to-earnings ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24. The stock’s fifty day moving average is $261.98 and its two-hundred day moving average is $245.08. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the company posted $2.77 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s payout ratio is presently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.